3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Waldenstrom Macroglobulinemia
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
Rituximab
30
Cyclophosphamide
25
Filgrastim
19
Methotrexate
15
fludarabine phosphate
13
Etoposide
13
Cytarabine
13
Peripheral Blood Stem Cell Transplantation
12
Cyclosporine
11
Vincristine
10
Mycophenolic Acid
10
Whole-Body Irradiation
9
Antilymphocyte Serum
9
Radiotherapy
8
Granulocyte Colony-Stimulating Factor
8
CT-P10
8
fludarabine
7
Prednisone
7
Doxorubicin
7
Dexamethasone
7
merphos
6
Tacrolimus
6
Melphalan
6
Calcium Dobesilate
6
dexamethasone acetate
5
dexamethasone 21-phosphate
5
deltacortene
5
auricularum
5
Methylprednisolone
5
Leucovorin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Burkitt Lymphoma
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts